Shareholder Alert: Robbins Arroyo LLP Announces Covetrus, Inc. (CVET) Sued for Misleading Shareholders

SAN DIEGO & PORTLAND, Maine–(BUSINESS WIRE)–$CVET #ClassAction–Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Covetrus, Inc. (NASDAQ: CVET) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between February 8, 2019 and August 12, 2019. Covetrus operates as an animal-health technology and services company.

If you suffered a loss as a result of Covetrus’ misconduct, click here.

Covetrus, Inc. (CVET) Accused of Misleading Shareholders

According to the complaint, on April 23, 2018, Henry Schein announced the spin-off and merger of the Animal Health Business of Henry Schein with Vets First Choice (“VFC”). Covetrus shares began trading on February 8, 2019. Throughout the class period and in the Offering Documents for the spin-merger, Henry Schein highlighted Covetrus’ strengths and touted Covetrus as a technology-enabled animal health business with a comprehensive service and technology platform and supply chain infrastructure. These benefits were reaffirmed later in Covetrus’ financial reports and the Company reassured that the integration was “on track” to hit financial targets. However, in reality, Covetrus’ strengths were overstated and the costs of the integration as well as the separation of Covetrus from Henry Schein had been much higher than represented. Then, on August 13, 2019, Covetrus shockingly reported a net loss of $0.09 per share rather than the expected increase of $0.17 per share and slashed its EBITDA guidance from estimates of $250 million to a realized $200 million. In its explanation, Covetrus confessed the undisclosed difficulties it was having in platform integration and separations costs from Henry Schein. Since this news, Covetrus’ stock has plummeted with a decline of $11.71, or 51%, per share and currently trades at around $11.50.

Covetrus, Inc. (CVET) Shareholders Have Legal Options

Contact us to learn more:

Leo Kandinov

(800) 350-6003

lkandinov@robbinsarroyo.com
Shareholder Information Form

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click Here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov

Robbins Arroyo LLP

lkandinov@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003

www.robbinsarroyo.com

Staff

Recent Posts

Creative Medical Technology Holdings Provides Corporate Update

PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a…

1 hour ago

GE HealthCare Unveils AI-Enabled Urology Software Feature Prostate Volume Assist

Prostate Volume Assist (PVA) is the company’s proprietary urology-based artificial intelligence (AI) software feature designed…

1 hour ago

Sutter Health Partners with Abridge on Generative AI Solution to Improve Patient, Physician Experience

PITTSBURGH & SACRAMENTO, Calif.--(BUSINESS WIRE)--Today, Abridge and Sutter Health announced they will make Abridge’s generative…

1 hour ago

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Presentations Will Feature Studies Evaluating TENEO™ Excimer Laser Platform, MIEBO® (Perfluorohexyloctane Ophthalmic Solution) and enVista®…

1 hour ago

Blackstone Life Sciences Announces Collaboration to Support Moderna’s Influenza Program

Blackstone Life Sciences to invest up to $750 million to support innovative mRNA technologyNEW YORK--(BUSINESS…

1 hour ago

Male Contraceptive Initiative Marks Women’s History Month With Investment in Birth Control Pill for Men

Phase 1a study of first hormone-free male pill completes enrollmentDURHAM, NC / ACCESSWIRE / March…

1 hour ago